Search
Hemab Therapeutics Holdings Ord Shs (Proposed)
COAGAdd to Watchlist
36.000USD
-0.730-1.99%
Market hours 09/24, 10:15（ET）
1.68BMarket Cap
0.00P/E TTM
COAG Analyst Recommendation Trends
In the current month, COAG has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. COAG average Analyst price target in the last month is 61.200.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
2
2
2
1
0
0
0
0
3
3
3
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
3
0
0
0
0
Financial Forecasting
Based on analysts' estimates, COAG EPS is projected to reach -0.520 in FY2026Q3, following reported EPS of -0.517 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
--
--
-0.74
-0.52
-0.58
Actual
-1.45
-0.51
-0.52
--
--
Surprise
--
--
+30.22%
--
--
FAQs
What is the analyst rating for Hemab Therapeutics Holdings Ord Shs (Proposed)?
Based on the ratings of Hemab Therapeutics Holdings Ord Shs (Proposed)'s stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.